Amendment includes finalized cash amount and updated CVR terms for tender offer LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that they have reached an agreement to... Read More

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii)... Read More

EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary... Read More

HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value Right EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously... Read More

EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27 th Annual Global Investment Conference. Mr. Hughes and Mr. Sitko will present on Monday, September 8, 2025 at 9:00 AM ET. The webcast for the... Read More

Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA Therapeutics. Company acquisitions: Announced XOMA Royalty’s acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax; acted as structuring agent and provided financing... Read More

- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously... Read More

XOMA Royalty adds milestone and royalty economics associated with two partnered assets EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today they have entered a definitive share purchase agreement (the “Purchase Agreement” and the transactions set forth in... Read More

EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”)... Read More

EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares,... Read More

EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab... Read More

Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immune thrombocytopenia Business development: Acquired an economic interest in Castle Creek Biosciences’ D-Fi (FCX-007) through... Read More

EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1 st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET. Mr.... Read More

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE... Read More

EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025. Mr. Sitko’s presentation will take place on Wednesday, April 9, 2025, at 10:30 AM PT. The presentation can be assessed... Read More

EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary... Read More

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s MIPLYFFA™ (arimoclomol) each received FDA approval Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024 EMERYVILLE, Calif.,... Read More

EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings. T.D. Cowen 45 th Annual Health Care Conference (March 3-5, 2025) Format: Date: Time: Corporate presentation Monday, March 3,... Read More

EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat on... Read More

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each... Read More

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in the fourth quarter of 2025 1 XOMA Royalty has the potential to net up... Read More

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts totaled $9.9 million in the third quarter, and $42.3 million for the first nine months of 2024 EMERYVILLE, Calif., Nov. 07, 2024 (GLOBE... Read More

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist... Read More

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones MIPLYFFA™ is now the sixth commercial asset in XOMA Royalty’s portfolio EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced... Read More

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences: H.C. Wainwright 26 th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment... Read More

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams,... Read More

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. “OJEMDA™ offers patients six months of age and older who have relapsed or... Read More

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2 nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat... Read More

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil... Read More

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene ® , an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category... Read More

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food... Read More

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KNTE) common... Read More

EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (“Kinnate”; Nasdaq: KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share (together with the base... Read More

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievement of certain development milestones during 2023 Added third commercial asset to XOMA’s portfolio with the acquisition of economic interests in DSUVIA® (sufentanil sublingual tablet)... Read More

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences: The 44 th Annual TD Cowen Health Care Conference taking place March 4-6, 2024, in Boston, MA. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a... Read More

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with the Base Price, the Cash Amount) at the closing of the merger plus a non-transferable contingent... Read More

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of Defense purchases XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments EMERYVILLE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has... Read More

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA) acceptance of Zevra Therapeutics’ New Drug Application (NDA) for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C (NPC), XOMA will make a $1 million milestone payment to LadRx. “NPC is an... Read More

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes has served as XOMA’s Executive Chairman and Interim Chief Executive Officer since January 1, 2023. “The rest of the Board and I have been impressed with Owen’s... Read More

EMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA’s first stock repurchase program, which permits the Company to purchase up to $50 million of XOMA’s common stock through January 2027. “Upon arriving at XOMA, Brad Sitko, our Chief Investment Officer and I made it very clear that we intended to be... Read More

EMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies EMERYVILLE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech... Read More

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple Phase 3 programs by year-end EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator,... Read More

EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted tovorafenib... Read More

EMERYVILLE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET. The conference is being held in New York, NY. The presentation can be accessed at https://bit.ly/3qJMUgT or by... Read More

Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Application in third quarter of 2023 EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator,... Read More

EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000 ® and Russell 3000 ® Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style... Read More

EMERYVILLE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin. Arimoclomol is a first-in-class investigational therapy that has completed a randomized,... Read More

EMERYVILLE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 financial results and highlighted recent operational achievements as the Company accelerates XOMA’s differentiated biotech royalty and milestone... Read More

EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 10:30 AM ET. The fireside chat can be accessed at https://bit.ly/403aHUp or by visiting the... Read More

EMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the commercial payment and a portion of the milestone rights to IXINITY® [coagulation factor IX (recombinant)], which is marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics. “Adding a new... Read More

EMERYVILLE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More

2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-single digit to low teens royalties, net, from Organon The Executive Leadership Team additions of Owen Hughes and Brad Sitko bring royalty investment and portfolio management expertise to... Read More

EMERYVILLE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the 43 rd Annual Cowen Health Care Conference on Tuesday, March 7, 2023, at 2:10 PM ET. The presentation can be accessed at https://bit.ly/3DmxDFH or by visiting the investor... Read More

EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes, the Company’s newly appointed Executive Chairman, two separate non-qualified stock options to purchase: (i) 100,000 shares of the Company’s common stock at an exercise price of $18.66 per share (the “First Hughes Inducement... Read More

Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Jim Neal has retired as Chief Executive Officer and two finance and biotechnology industry veterans have joined in newly created executive leadership roles to drive the... Read More

EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of... Read More